Thomas E. Polen, Jr. net worth and biography

Thomas Polen, Jr. Biography and Net Worth

Tom Polen is the chairman, CEO and president of BD (Becton, Dickinson and Company). Polen leads the $20 billion global medical technology company headquartered in Franklin Lakes, NJ, and works alongside 75,000+ BD associates who are making an impact and fulfilling the company’s purpose of advancing the world of health™.

Polen is focused on advancing BD’s role in redefining the future of healthcare through innovative technologies and solutions that are changing people’s lives. Under his leadership and long-term strategy for growth, he has focused the organization’s BD 2025 strategy around three pillars—Grow, Simplify, and Empower—which drive and accelerate the innovation of advanced, cutting-edge technologies.

Polen brings more than 25 years of experience in medical technology. He started at BD in 1999 through the acquisition of an early phase start-up. In 2004, he joined Baxter Healthcare, where he led the injectable pharmaceuticals business. Since returning to BD in 2009, Polen has served in a variety of leadership roles, including as president of several worldwide business units within BD’s Life Sciences segment and later as president of the BD Medical segment, during which he led the $12 billion acquisition of CareFusion, spearheading the company’s expansion into informatics and digital health solutions. In 2017, he led the strategy for the $24 billion acquisition of C. R. Bard, Inc. and shortly thereafter was named president and chief operating officer of BD. Polen became CEO in January 2020 and chairman of the board of directors in April 2021.

Polen serves on the board of directors of Advamed and Hackensack Meridian Health Center for Discovery and Innovation. He is a member of the American Heart Association CEO Roundtable and actively supports the Children’s Tumor Foundation, as well as several associations committed to helping patients with breast cancer. Polen also serves on the Advisory Committee on Supply Chain Competitiveness for the U.S. Department of Commerce’s International Trade Administration.

Polen holds a bachelor’s degree from Salisbury University and a master’s in business administration from Johns Hopkins University.

What is Thomas E. Polen, Jr.'s net worth?

The estimated net worth of Thomas E. Polen, Jr. is at least $7.25 million as of August 15th, 2022. Mr. Polen, Jr. owns 28,878 shares of Becton, Dickinson and stock worth more than $7,250,688 as of December 1st. This net worth approximation does not reflect any other investments that Mr. Polen, Jr. may own. Learn More about Thomas E. Polen, Jr.'s net worth.

How do I contact Thomas E. Polen, Jr.?

The corporate mailing address for Mr. Polen, Jr. and other Becton, Dickinson and executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and can also be reached via phone at (201) 847-6800. Learn More on Thomas E. Polen, Jr.'s contact information.

Has Thomas E. Polen, Jr. been buying or selling shares of Becton, Dickinson and?

Thomas E. Polen, Jr. has not been actively trading shares of Becton, Dickinson and over the course of the past ninety days. Most recently, Thomas E. Polen, Jr. sold 9,500 shares of the business's stock in a transaction on Monday, August 15th. The shares were sold at an average price of $265.13, for a transaction totalling $2,518,735.00. Following the completion of the sale, the chief executive officer now directly owns 28,878 shares of the company's stock, valued at $7,656,424.14. Learn More on Thomas E. Polen, Jr.'s trading history.

Who are Becton, Dickinson and's active insiders?

Becton, Dickinson and's insider roster includes Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Roland Goette (EVP), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and?

During the last year, insiders at the medical instruments supplier sold shares 10 times. They sold a total of 45,277 shares worth more than $12,052,252.30. The most recent insider tranaction occured on August, 15th when EVP David Hickey sold 475 shares worth more than $125,875.00. Insiders at Becton, Dickinson and own 0.5 % of the company. Learn More about insider trades at Becton, Dickinson and.

Information on this page was last updated on 8/15/2022.

Thomas E. Polen, Jr. Insider Trading History at Becton, Dickinson and

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/15/2022Sell9,500$265.13$2,518,735.0028,878View SEC Filing Icon  
11/19/2018Sell5,243$243.86$1,278,557.98View SEC Filing Icon  
3/13/2018Sell1,877$227.00$426,079.0015,387View SEC Filing Icon  
8/9/2017Sell5,971$197.41$1,178,735.1112,861View SEC Filing Icon  
12/1/2015Sell2,683$152.21$408,379.435,789View SEC Filing Icon  
5/22/2015Sell3,882$142.56$553,417.92View SEC Filing Icon  
See Full Table

Thomas E. Polen, Jr. Buying and Selling Activity at Becton, Dickinson and

This chart shows Thomas E Polen Jr's buying and selling at Becton, Dickinson and by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Overview

Becton, Dickinson and logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $251.08
Low: $249.40
High: $254.33

50 Day Range

MA: $228.62
Low: $218.29
High: $241.02

2 Week Range

Now: $251.08
Low: $215.90
High: $280.62

Volume

44,070 shs

Average Volume

1,813,421 shs

Market Capitalization

$71.15 billion

P/E Ratio

42.70

Dividend Yield

1.44%

Beta

0.61